IDiyas

For the Inventor, By the Inventor

Maulburg, Germany

Marina Tintelnot-Blomley

USPTO Granted Patents = 18 

 

Average Co-Inventor Count = 6.6

ph-index = 5

Forward Citations = 137(Granted Patents)


Company Filing History:

goldMedal18 out of 3,923 
 
Novartis Ag
 patents

Years Active: 2009-2020

where 'Filed Patents' based on already Granted Patents

18 patents (USPTO):
1. 10683287 - Heterocyclic derivatives and their use in the treatment of neurological disorders (2020-06-16),
2. 10442808 - Pyrazolo pyrimidine derivatives and their use as MALT1 inhbitors (2019-10-15),
3. 10301296 - Heterocyclic derivatives and their use in the treatment of neurological disorders (2019-05-28),
4. 10035794 - Heterocyclic derivatives and their use in the treatment of neurological disorders (2018-07-31),
5. 9815842 - Pyrazolo pyrimidine derivatives and their use as MALT1 inhibitors (2017-11-14),
6. 9670193 - Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease (2017-06-06),
7. 9550758 - Heterocyclic derivatives and their use in the treatment of neurological disorders (2017-01-24),
8. 9284284 - Oxazine derivatives and their use in the treatment of disease (2016-03-15),
9. 9056843 - Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease (2015-06-16),
10. 8865712 - Heterocyclic derivatives and their use in the treatment of neurological disorders (2014-10-21),
11. 8637508 - Heterocyclic derivatives and their use in the treatment of neurological disorders (2014-01-28),
12. 8207164 - Oxazine derivatives and their use in the treatment of neurological disorders (2012-06-26),
13. 8093406 - Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors (2012-01-10),
14. 8039455 - Macrocyclic compounds useful as BACE inhibitors (2011-10-18),
15. 8008250 - Macrocyclic compounds and compositions useful as BACE inhibitors (2011-08-30),

Title: Marina Tintelnot-Blomley: Pioneering Innovation for a Sustainable Future

Introduction:

Marina Tintelnot-Blomley, an esteemed inventor based in Maulburg, DE, is celebrated for her unwavering commitment to innovation and sustainability. With a total of 18 patents to her name, she has solidified her position as a visionary inventor whose work continues to inspire others in the field.

Latest Patents:

Tintelnot-Blomley's most recent patents showcase her dedication to advancing healthcare and medical research. Her groundbreaking inventions include novel heterocyclic compounds for the treatment of neurological disorders, particularly Alzheimer's Disease and diabetes. Additionally, she has introduced new pyrazolo-pyrimidine derivatives that act as MALT1 inhibitors, opening new possibilities for medicinal interventions.

Career Highlights:

Throughout her illustrious career, Tintelnot-Blomley has consistently pushed the boundaries of innovation. Her expertise in developing pharmaceutical compositions and medicaments has garnered recognition within the industry. As a key figure at Novartis AG, she has contributed significantly to the advancement of cutting-edge medical solutions.

Collaborations:

Tintelnot-Blomley is known for her collaborative spirit, having worked closely with esteemed colleagues such as Rainer Machauer and Siem Jacob Veenstra. Their synergistic efforts have led to the creation of revolutionary inventions that have the potential to shape the future of medicine.

Conclusion:

Marina Tintelnot-Blomley's pioneering spirit and dedication to sustainability underscore her status as a trailblazing inventor. Her remarkable contributions to the field of healthcare and pharmaceuticals serve as a testament to her innovative prowess and unwavering commitment to creating a better tomorrow.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…